After FibroGen’s FDA rejection in anemia, Akebia CEO aims to seize first-in-class opening with vadadustat
In the race for novel oral drugs to treat anemia of chronic kidney disease, AstraZeneca and FibroGen’s roxadustat held the front-runner position for quite some time. ...
Continue Reading →
